 CytomX Therapeutics Inc NASDAQ: CTMX announced preliminary Phase 2 results of CX-2029 in patients with either advanced squamous non-small cell lung cancer sqNSCLC or head and neck squamous cell carcinoma HNSCC. The CD71-directed conditionally activated antibody-drug conjugate ADC is being co-developed by CytomX and AbbVie Inc NYSE: ABBV. 